Planegg-Martinsried, Germany, 22 March 2024 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 2023, presenting all material reporting period developments and providing an outlook for 2024. The full report is available at 4SC’s website. Jason Loveridge, Ph.D., CEO of 4SC, commented: “2023 was a real breakout year for […]
Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio 20 March 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received a Notice of Allowance from the US Patent Office in […]
Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5 Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms at different dosing regimens Revolutionizing treatment options for multiple myeloma patients with its proprietary novel payload with a unique mode of action Ladenburg, Germany, 18 March 2024 […]
Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses Expanding R&D team to further develop AT-108 and broaden in vivo reprogramming […]
Autotaxin inhibitor, IOA-289, recently received the proposed INN cambritaxestat Cambritaxestat is in the Phase I AION-02 trial in combination with chemotherapy in metastatic pancreatic cancer It is the first autotaxin inhibitor to be investigated in cancer patients Amsterdam, The Netherlands and Geneva, Switzerland, 7 March 2024 – iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer […]
